Issue link: https://viewer.e-digitaledition.com/i/321198
AT THE BEGINNING OF this year, the Centers for Medicare & Medicaid Services (CMS) — a divi- sion of the U.S. Department of Health and Human Services — proposed a new rule in the Medicare Part D prescription drug program to crack down on what's becoming an increasingly bigger issue in the U.S. healthcare industry: prescription fraud and abuse. Here is a look at the controversial rule and how it may impact your practice. Overall, the proposed rule would provide CMS with broader authority to take action against individuals or entities who commit fraud or abuse in the Part D program in the following three ways. First, it would require all prescribers of Part D drugs to enroll in Medicare in order for their prescriptions to be covered under Part D. Second, it would permit CMS to revoke a physician's Medicare enrollment if he or she repeatedly prescribes Part D drugs in an abusive manner. Finally, a physician's Medicare enrollment could be rescinded if the Drug Enforcement Agency or appropri- ate state licensing agency has revoked or suspended the physician's license. The fed- eral government believes these measures will save money in the Medicare program and ensure that only qualified physicians can prescribe prescription drugs. By Stuart T. O'Neal III, Esquire +++++++++++++ +++ + +++ + +++++++++++++ LEGAL How the Proposed New Rule for Medicare Part D Stuart T. O'Neal III, Esquire MAY IMPACT YOUR PRACTICE The proposed rule would also stream- line fraud investigation procedures. Specifically, it would allow CMS to collect information directly from pharmacies and other "downstream entities" when investigating fraud claims. Under the current system, the agency must work through Plan B plan sponsors to obtain information from pharmacies and related entities, which wastes valuable time and resources during a fraud investigation. Given this more streamlined process, it would be advantageous from a practice point of view to have clear internal pro- tocols in place to ensure compliance with these new regulations. One of the pillars of a potential successful defense, from a regulatory and/or litigation perspective, is to point to these protocols to show an investigatory body that: + Mechanisms exist to spot red flags relative to suspicious or abusive prescription practices. + Checks and balances remain in place to prevent suspicious activity. + Expectations and boundaries are set immediately to prevent and possibly deter prescription writing abuse. The proposed rule has created sig- nificant discussion and controversy since it was first issued, generating nearly 7,500 public comments during its period of open comment. While the Obama administration dropped other, more controversial elements of the proposed rule after receiving significant political backlash, the antifraud and abuse propos- als outlined above remain intact, with CMS working on crafting a final rule in the coming months. The healthcare litigation team at Burns White can assist groups in foresee- ing possible pitfalls in current practice management in an effort to facilitate com- pliance with these new requirements, and potentially avoid a fraud investigation. The firm is also equipped to handle instances in which an investigation is, or already has been, initiated by an outside agency. Healthcare litigator Stuart T. O'Neal III is based out of the Philadelphia and Wilkes-Barre offices of Burns White. His practice focuses on the defense of medical facilities, long-term care facilities and profes- sionals of all types in various professional, general liability, commercial litigation and employment matters in state court, federal court and at the administrative level. O'Neal has also been called upon by clients to handle internal investigations centered on internal audits, misappropriation of funds and embezzlement. He can be reached at soneal@burnswhite.com. ■ M D N E W S . CO M ■ MD NEWS Eastern Pennsylvania/NW New Jersey | 5

